About Glucoside xylosyltransferase 2
Glucoside xylosyltransferase 2 (GXYLT2) is a protein
from Homo sapiens identified by UniProt accession
A0PJZ3, 443 residues long.
MolForge cross-references it against 0 known binders and
56 disease associations.
Target properties
| Protein name | Glucoside xylosyltransferase 2 |
|---|
| UniProt accession | A0PJZ3 |
|---|
| Gene | GXYLT2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 443 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (56)
Diseases linked to this target (Open Targets).
- urate measurement · score 0.32
- bone density · score 0.32
- motion sickness · score 0.28
- monocyte count · score 0.10
- neurofibrillary tangles measurement · score 0.09
- protein measurement · score 0.08
- bladder transitional cell carcinoma · score 0.07
- PHF-tau measurement · score 0.07
- Abnormality of refraction · score 0.06
- neoplasm · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A0PJZ3-F1 | alphafold | PREDICTED | 83.13 | — |
Amino-acid sequence (443 residues)
MKLRSKAAAL LLLALAALLL ALLSLRAGRA EPPALPARPA SAPQRHPAPV PARWPGPGAL PGASPGVRRR RPPRPRPRAG RRGAARLEKL ARRPGEPRSF QAVLPPELWI HLAVVACGNR LEETLVMLKS AVLFSHRKIQ FHIFTEDSLK PEFDKQLRQW PDSYTKKFEH RIYPITFSVG NPQEWKKLFK PCAAQRLFLP VILKDVDSLL YVDTDVLFLR PVDDIWKLLR LFNSTQLAAM APEHEIPKIG WYSRFARHPF YGSAGVNSGV MLMNLTRIRS TQFKNSMIPT GLAWEDMLYP LYQKYKNAIT WGDQDLLNII FYFNPECLYV FPCQWNYRPD HCMYGSNCRE AEHEGVSVLH GNRGVYHDDK QPTFRALYEA IRDFPFQDNL FQSMYYPLQL KFLETVHTLC GRIPQVFLKQ IEKTMKRAYE KHVIIHVGPN QMH
Explore Glucoside xylosyltransferase 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets